Wu Guizhen, the CDC's chief biosafety expert, revealed during a Monday night program on Chinese public service broadcaster CCTV that clinical trials of several vaccine candidates have been progressing well and preparations are now being made for the drugs to go into mass production.
It is still subject to approval from regulators at the US Food and Drug Administration (FDA).
United Kingdom scientists are to test a pair of leading coronavirus vaccine candidates to see if they work better when inhaled than when injected. In addition to this, they confirmed that the pause will continue till AstraZeneca restarts the trials. The late-stage trial involves around 30,000 participants in the US, UK, Brazil, and South Africa.
The vaccine candidate from Pfizer and its German partner BioNTech uses part of the pathogen's genetic code called messenger RNA, or mRNa.
The problem in the UK?
A representative for AstraZeneca declined to comment. However, at the start of September, respected British medical journal The Lancet published a study prepared by the developers of Sputnik V, showing it to be 100 percent effective, producing antibodies in all 76 participants of early-stage trials. Researchers will be allowed some time with this step. They pledged to prioritise safety and "uphold the integrity of the scientific process" as they each developed vaccines.
AstraZeneca and Oxford University contracted the Pune based firm, which is the world's largest manufacturer of vaccines.
About one in seven volunteers who received a groundbreaking Russian coronavirus vaccine have complained of side effects such as muscle pain, weakness, and fever, according to the country's Minister for Health Mikhail Murashko.
Shares of AstraZeneca AZN.L inched higher in early trade on Monday as the optimism spurred by the British drugmaker's resumption of clinical trials for its COVID-19 vaccine candidate outweighed official weekend moves to cut US drug prices.
Pfizer also submitted a proposal to the FDA on Saturday (12 September) that would see its late stage trial expanded, including up to 44,000 participants.